AgenoLAB Broadens Service Offering for Drug Development with Roche's RTCA Cardio Instrument

Penzberg, Germany, 12. Mai 2011

AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche (SIX: RO, ROG; OTCQX: RHHBY). The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.

“We are pleased to be the first lab in Germany that purchased Roche´s RTCA Cardio Instrument. This latest member of the xCELLigence product family complements and extends our service offering, which has always included the latest xCELLigence developments since 2008. The new impedance-based technology for measuring the contraction activity of heart cells will open the door to completely new analytical workflows in pharmaceutical drug development,” stated Dr. Michaela Noll, Head of Cell Systems and Tissue Engineering at AgenoLAB.

Dr. med. Andreas Greither, CEO of AgenoLAB, added: “Cardiotoxicity screening, e.g. for compilation of preclinical safety data, complements our service portfolio for the measurement of in vitro toxicity, dermatotoxicity, and chemical-cosmetic screening of active ingredients. For AgenoLAB, the improved qualification and GMP-like validation of planned processes were the decisive factors to use the xCELLigence Cardio System.”

The RTCA Cardio Instrument, a medium-throughput cell analyzer, utilizes impedance readings to monitor cardiac beating and cellular events in real time, featuring a unique detection rate and frequency measurement concept as well as dedicated software. Unlike synergistic techniques, such as the patch clamp, the new system can be used in a fully controlled environment for continuous short-term and long-term experiments, thus improving the applicable experimental time as well as the reproducibility and data quality.  The instrument is the only 96-well, cardiotoxicity screening system on the market for continuous, real-time, label-free cardiomyocyte beating analysis. It can be used in conjunction with cardiomyocytes derived from human or mouse stem cells for assessing the cardiac safety profile of lead compounds or drug candidates during drug development. For more information, please see

About AgenoLAB

AgenoLAB GmbH & Co. KG, located in Stuttgart, Germany, is an innovative Biotechnology & Life Science Laboratory for safety and activity testing services and R & D. The international activities provided by AgenoLAB contain tissue engineering, cell culture, in-vitro toxicology and compound testing, microbiology by Microseq and Maldi-TOF analytics, molecular biology, GMP-conform production, and quality assurance. Our services include quality control for pharmaceutical companies, cosmetics, chemicals (REACH), medical devices, foods, and research. Contact:

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

For life science research only. Not for use in diagnostic procedures.
XCELLIGENCE is a trademark of Roche.